Safety-Related Labeling Changes
No dose adjustment is needed when ponesimod is co-administered with strong CYP3A4 and UGT1A1 inducers
Trade Name
Ponvory
Updated Section
4.5. Interactions with other medicinal products
Month
Dec, 2024